Why Alnylam Pharmaceuticals, Inc. (ALNY) stock moved
No significant move on Nov 19, 2026 (−1.1%, close-to-close). Latest notable session: Nov 18, 2026.
Why Alnylam Pharmaceuticals, Inc. (ALNY) fell 4.5% on November 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) fell 4.5% on November 18, 2026, closing at $149.40 versus $156.50 the prior session (close-to-close, from daily closes). After Aberdeen Group plc trimmed its stake in the company, as reported by DefenseWorld. The decline occurred on below-average volume (0.57x expected at this point in the session), suggesting modest institutional repositioning rather than broad-based selling. Source: defenseworld.net.
Alnylam Pharmaceuticals fell 3.30% to $151.33 after Aberdeen Group plc trimmed its stake in the company, as reported by DefenseWorld. The decline occurred on below-average volume (0.57x expected at this point in the session), suggesting modest institutional repositioning rather than broad-based selling.
What to watch next: Alnylam's earnings release scheduled for February 11, 2027, with consensus EPS estimate of $1.73; watch for any analyst commentary following the Jefferies conference and monitor for additional institutional position changes.
Earlier sessions that moved ALNY
- −3.2%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +5.4%A Pomerantz Law Firm investor alert issued November 12, 2026, flags an ongoing investigation into claims on behalf of ALNY shareholders—typically a headwind—yet the stock advanced on above-normal volume (1.84x expected at this time of day).
- +5.4%The company announced five-year HELIOS-B data showing sustained AMVUTTRA benefit in ATTR-CM patients, and collaborator Regeneron reported positive first-in-human data for the jointly developed CIDEBsiRNA in MASLD patients.
- −3.2%Alnylam is trading lower amid investor concerns over slower-than-expected demand conversion for Amvuttra in the ATTR-CM market, following Q3 2026 earnings and subsequent analyst downgrades from Raymond James, Truist Financial, and Goldman Sachs.
- −2.7%Driven by a combination of Q3 earnings fallout and corporate leadership turnover.
- −4.2%Following Wall Street analyst downgrades and price target cuts issued in the wake of the company's Q3 2026 earnings report.
- −5.2%Following its Q3 earnings report filed today, extending a sharp sell-off triggered by slower-than-expected demand for its flagship transthyretin (TTR) franchise.
- −25.1%Alnylam Pharmaceuticals reported third-quarter 2026 earnings today, revealing slower-than-expected patient demand growth for its key drug Amvuttra (vutrisiran) in ATTR cardiomyopathy despite sales force expansion, with management noting performance is trending toward the lower end of guidance ranges (investors.alnylam.com). Read the October 29, 2026 analysis →
- +3.6%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −5.0%Driven by ongoing investor concerns over competitive pressure in the ATTR-CM treatment market—particularly strong sales momentum from BridgeBio's Attruby—combined with the company's earlier downward revisions to full-year TTR net product revenue guidance, per the web synthesis.
- −6.3%JPMorgan trimmed its price target on the stock and warned that near-term results could face friction.
- −2.9%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +2.6%ALNY moved +2.77% from its $249.05 open to a $255.96 close on 2026-09-25.
- −4.7%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −4.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Alnylam Pharmaceuticals, Inc. (ALNY) shares fell 1.1% to $147.82 at the November 19, 2026 close, a modest decline from the prior close of $149.40. That close is the latest confirmed price for ALNY; a live quote was not available. BestStocks flagged the session as a major change for ALNY. The move is tied to company news. Below, we break down what changed for ALNY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Alnylam management scheduled to present at Piper Sandler's December healthcare investor conference. Investor conference presentations offer platform to discuss pipeline progress and corporate strategy directly to institutional investors.
What it means for Alnylam Pharmaceuticals, Inc. investors
For Alnylam Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Material negative event; Negative session, down 1.1%. BestStocks rates the overall signal quality weak (30/100). With earnings roughly 83 days out, the next report is the most likely near-term test of the move.
ALNY price reaction
ALNY last traded at $147.82, down $1.58 (-1.06%) from the previous close of $149.40. Over the past month the stock has ranged between $147.82 and $232.40, and it currently sits about 0% of the way up that band.
The bull and bear case for ALNY stock
Weighing the constructive signals against the risks, here is how the bull and bear case for Alnylam Pharmaceuticals, Inc. (ALNY) lines up on the latest data.
The bullish case
- Positive price momentum.
The bearish case
- Material negative event.
- Negative session, down 1.1%.
- Alnylam Pharmaceuticals fell 3.30% to $151.33 after Aberdeen Group plc trimmed its stake in the company, as reported by DefenseWorld.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Previous notable changes for ALNY
In-depth ALNY event analyses
Frequently asked questions about ALNY
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock move?
Alnylam Pharmaceuticals, Inc. (ALNY) fell 4.5% on November 18, 2026, closing at $149.40 versus $156.50 the prior session (close-to-close, from daily closes). After Aberdeen Group plc trimmed its stake in the company, as reported by DefenseWorld. The decline occurred on below-average volume (0.57x expected at this point in the session), suggesting modest institutional repositioning rather than broad-based selling. Source: defenseworld.net.
How much did ALNY stock fall?
ALNY lost 1.06% ($1.58) versus the prior close of $149.40, last trading at $147.82.
When is Alnylam Pharmaceuticals, Inc.'s next earnings date?
ALNY's next earnings report is scheduled for 2027-02-11 — about 83 days away.
How BestStocks tracks ALNY
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for ALNY, cross-checked against the data sources listed below. A live intraday quote was not available, so price and volume figures are the confirmed end-of-day close from November 19, 2026 — not the current price — and the percentage move is that session's. They refresh once live quotes resume. For companies with multiple share classes, market-cap figures can differ by data source. This is an educational summary of what changed and why — not personalized investment advice.
